Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro

Abstract Background Ricin A chain (RTA) and Pokeweed antiviral proteins (PAPs) are plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs) isolated from Ricinus communis and Phytolacca Americana respectively. This study was to investigate the potential production amenability and sub-toxic...

Full description

Bibliographic Details
Main Authors: Yasser Hassan, Sherry Ogg, Hui Ge
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Biotechnology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12896-018-0458-6
id doaj-6b082df1389c48fa8484008bfa7ed90e
record_format Article
spelling doaj-6b082df1389c48fa8484008bfa7ed90e2020-11-25T01:22:54ZengBMCBMC Biotechnology1472-67502018-08-0118111110.1186/s12896-018-0458-6Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitroYasser Hassan0Sherry Ogg1Hui Ge2Ophiuchus Medicine Inc.Johns Hopkins University, AAPAscentGene Inc.Abstract Background Ricin A chain (RTA) and Pokeweed antiviral proteins (PAPs) are plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs) isolated from Ricinus communis and Phytolacca Americana respectively. This study was to investigate the potential production amenability and sub-toxic antiviral value of novel fusion proteins between RTA and PAPs (RTA-PAPs). In brief, RTA-Pokeweed antiviral protein isoform 1 from seeds (RTA-PAPS1) was produced in an E. coli in vivo expression system, purified from inclusion bodies using gel filtration chromatography and protein synthesis inhibitory activity assayed by comparison to the production of a control protein Luciferase. The antiviral activity of the RTA-PAPS1 against Hepatitis B virus (HBV) in HepAD38 cells was then determined using a dose response assay by quantifying supernatant HBV DNA compared to control virus infected HepAD38 cells. The cytotoxicity in HepAD38 cells was determined by measuring cell viability using a tetrazolium dye uptake assay. The fusion protein was further optimized using in silico tools, produced in an E. coli in vivo expression system, purified by a three-step process from soluble lysate and confirmed in a protein synthesis inhibition activity assay. Results Results showed that RTA-PAPS1 could effectively be recovered and purified from inclusion bodies. The refolded protein was bioactive with a 50% protein synthesis inhibitory concentration (IC50) of 0.06 nM (3.63 ng/ml). The results also showed that RTA-PAPS1 had a synergetic activity against HBV with a half-maximal response concentration value (EC50) of 0.03 nM (1.82 ng/ml) and a therapeutic index of > 21,818 with noticeable steric hindrance. Results also showed that the optimized protein ricin A chain mutant-Pokeweed antiviral protein isoform 1 from leaves (RTAM-PAP1) could be recovered and purified from soluble lysates with gain of function on protein synthesis inhibition activity, with an IC50 of 0.03 nM (1.82 ng/ml), and with minimal, if any, steric hindrance. Conclusions Collectively, our results demonstrate that RTA-PAPs are amenable to effective production and purification in native form, possess significant gain of function on protein synthesis inhibition and anti-HBV activities in vitro with a high therapeutic index and, thus, merit further development as potential potent antiviral agents against chronic HBV infection to be used as a standalone or in combination with existent therapies.http://link.springer.com/article/10.1186/s12896-018-0458-6Fusion proteinsRicinPokeweed antiviral proteinHepatitis B virusAntiviral agentRibosome-inactivating proteins
collection DOAJ
language English
format Article
sources DOAJ
author Yasser Hassan
Sherry Ogg
Hui Ge
spellingShingle Yasser Hassan
Sherry Ogg
Hui Ge
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
BMC Biotechnology
Fusion proteins
Ricin
Pokeweed antiviral protein
Hepatitis B virus
Antiviral agent
Ribosome-inactivating proteins
author_facet Yasser Hassan
Sherry Ogg
Hui Ge
author_sort Yasser Hassan
title Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
title_short Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
title_full Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
title_fullStr Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
title_full_unstemmed Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
title_sort expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (rta-paps) in escherichia coli and their inhibition of protein synthesis and of hepatitis b virus in vitro
publisher BMC
series BMC Biotechnology
issn 1472-6750
publishDate 2018-08-01
description Abstract Background Ricin A chain (RTA) and Pokeweed antiviral proteins (PAPs) are plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs) isolated from Ricinus communis and Phytolacca Americana respectively. This study was to investigate the potential production amenability and sub-toxic antiviral value of novel fusion proteins between RTA and PAPs (RTA-PAPs). In brief, RTA-Pokeweed antiviral protein isoform 1 from seeds (RTA-PAPS1) was produced in an E. coli in vivo expression system, purified from inclusion bodies using gel filtration chromatography and protein synthesis inhibitory activity assayed by comparison to the production of a control protein Luciferase. The antiviral activity of the RTA-PAPS1 against Hepatitis B virus (HBV) in HepAD38 cells was then determined using a dose response assay by quantifying supernatant HBV DNA compared to control virus infected HepAD38 cells. The cytotoxicity in HepAD38 cells was determined by measuring cell viability using a tetrazolium dye uptake assay. The fusion protein was further optimized using in silico tools, produced in an E. coli in vivo expression system, purified by a three-step process from soluble lysate and confirmed in a protein synthesis inhibition activity assay. Results Results showed that RTA-PAPS1 could effectively be recovered and purified from inclusion bodies. The refolded protein was bioactive with a 50% protein synthesis inhibitory concentration (IC50) of 0.06 nM (3.63 ng/ml). The results also showed that RTA-PAPS1 had a synergetic activity against HBV with a half-maximal response concentration value (EC50) of 0.03 nM (1.82 ng/ml) and a therapeutic index of > 21,818 with noticeable steric hindrance. Results also showed that the optimized protein ricin A chain mutant-Pokeweed antiviral protein isoform 1 from leaves (RTAM-PAP1) could be recovered and purified from soluble lysates with gain of function on protein synthesis inhibition activity, with an IC50 of 0.03 nM (1.82 ng/ml), and with minimal, if any, steric hindrance. Conclusions Collectively, our results demonstrate that RTA-PAPs are amenable to effective production and purification in native form, possess significant gain of function on protein synthesis inhibition and anti-HBV activities in vitro with a high therapeutic index and, thus, merit further development as potential potent antiviral agents against chronic HBV infection to be used as a standalone or in combination with existent therapies.
topic Fusion proteins
Ricin
Pokeweed antiviral protein
Hepatitis B virus
Antiviral agent
Ribosome-inactivating proteins
url http://link.springer.com/article/10.1186/s12896-018-0458-6
work_keys_str_mv AT yasserhassan expressionofnovelfusionantiviralproteinsricinachainpokeweedantiviralproteinsrtapapsinescherichiacoliandtheirinhibitionofproteinsynthesisandofhepatitisbvirusinvitro
AT sherryogg expressionofnovelfusionantiviralproteinsricinachainpokeweedantiviralproteinsrtapapsinescherichiacoliandtheirinhibitionofproteinsynthesisandofhepatitisbvirusinvitro
AT huige expressionofnovelfusionantiviralproteinsricinachainpokeweedantiviralproteinsrtapapsinescherichiacoliandtheirinhibitionofproteinsynthesisandofhepatitisbvirusinvitro
_version_ 1725124732803612672